Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism

Trial Profile

Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Dalteparin sodium; Enoxaparin sodium; Fondaparinux sodium; Tinzaparin sodium; Warfarin
  • Indications Venous thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms EINSTEIN Junior Phase III
  • Sponsors Bayer; Bayer HealthCare; Janssen Research & Development
  • Most Recent Events

    • 08 Jul 2019 According to a Bayer media release, the company will submit an application to the European Medicines Agency (EMA) for the extension of the Xarelto marketing authorization to make this new treatment option, including the granules for oral suspension, available for children with venous thromboembolism.
    • 08 Jul 2019 Results presented in a Bayer media release.
    • 08 Jul 2019 Primary endpoint has been met. (Composite number of overt major and clinically relevant non-major bleeding.), according to a Janssen Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top